To review the safety and efficacy of chronic metoclopramide for diabetic gastroparesis.
DATA SOURCES
Medical literature was accessed through MEDLINE (1965 to October 2002) and PubMed (1965 to October 2002). Key search terms included metoclopramide; diabetic gastroparesis; and dyskinesia, drug induced.
DATA SYNTHESIS
Metoclopramide is often used for diabetic gastroparesis, despite the risk of tardive dyskinesia. Published information is limited regarding long-term efficacy and toxicity of metoclopramide. The literature was assessed concerning these topics.
CONCLUSIONS
Limited data do not provide sufficient evidence to conclude whether metoclopramide is efficacious for chronic use. Routine monitoring may mitigate the risk associated with metoclopramide therapy.
. KochKL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology and treatment. Dig Dis Sci1999; 44: 1061–75.
2.
. DrenthJP, EngelsLG. Diabetic gastroparesis: a critical reappraisal of new treatment strategies. Drugs1992; 44: 537–53.
3.
. JonesKL, RussoA, StevensJE, WishartJM, BerryMK, HorowitzM. Predictors of delayed gastric emptying in diabetes. Diabetes Care2001; 24: 1264–9.
4.
. HorowitzM, SuY, RaynerCK. Gastroparesis: prevalence, clinical significance and treatment. Can J Gastroenterol2001; 14: 805–13.
5.
. MelgaP, MansiC, CiuchiE, GiustiR, SciabaL, PrandoR. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care1997; 20: 55–8.
6.
. WysowskiDK, CorkenA, Gallo-TorresH, TalaricoL, RodriguezEM. Postmarketing reports of QT prolongation and ventricular arrythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol2001; 96: 1698–1703.
7.
. BaroneJA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother1999; 33: 429–40.
8.
. PattersonD, AbellT, RothsteinR, KochK, BarnettJ. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol1999; 94: 1230–4.
9.
. JanssensJ, PeetersTL, VantrappenG, TackJ, UrbainJL, De RooM, et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin: preliminary studies. N Engl J Med1990; 322: 1028–31.
10.
. PaiMP, GraciDM, AmsdenGW. Macrolide drug interactions: an update. Ann Pharmacother2000; 34: 495–513.
. SnapeWJ, BattleWM, SchwartzSS, BraunsteinSN, GoldsteinHA, AbassA. Metoclopramide to treat gastroparesis due to diabetes mellitus: a double-blind controlled trial. Ann Intern Med1982; 96: 444–6.
13.
. RicciDA, SaltzmanMB, MeyerC, CallachanC, McCallumRW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol1985; 7: 25–32.
14.
. McCallumRW, RicciDA, RakatanskyH, BeharJ, RhodesJB, SalenG, et al. A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care1983; 6: 463–7.
15.
. LooFD, PalmerDW, SoergelKH, KalbfleischJH, WoodCM. Gastric emptying in patients with diabetes mellitus. Gastroenterology1984; 86: 485–94.
16.
. SchadeRR, DugasMC, LhotskyDM, GavalerJS, VanThielDH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci1985; 30: 10–5.
17.
. AlbibiR, McCallumRW. Metoclopramide: pharmacology and clinical application. Ann Intern Med1983; 98: 86–95.
. MillerLG, JankovicJ. Metoclopramide-induced movement disorders: clinical findings with a review of the literature. Arch Intern Med1989; 149: 2486–92.
20.
. GanziniL, CaseyDE, HoffmanWF, McCallAL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med1993; 153: 1469–75.
. GuoJP, MaurerAH, FisherRS, ParkmanHP. Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci2001; 46: 24–9.
23.
. WoernerMG, SaltzBL, KaneJM, LiebermanJA, AlvirJM. Diabetes and development of tardive dyskinesia. Am J Psychiatry1993; 150: 966–8.
24.
. BeglingerC. Tegaserod: a novel, selective 5-HT4 receptor partial agonist for irritable bowel syndrome. Int J Clin Pract2002; 56: 47–51.
25.
. RabineJD, BarnettJL. Management of the patient with gastroparesis. J Clin Gastroenterol2001; 32: 11–8.
26.
. US Food and Drug Administration — Center for Devices and Radiological Health [cited 2002 June 21]. Available from: URL:http://www.fda.gov/cdrh/pdf/h990014a.pdf.
27.
. EzzeddineD, KatzN, GopalswamyN, BhutaniMS. Pyloric injection of botulinum toxin for the treatment of diabetic gastroparesis. Gastrointest Endosc2002; 55: 920–3.
28.
. MunetzMR, BenjaminS. How to examine patients using the abnormal involuntary movement scale. Hosp Community Psychiatry1988; 39: 1172–7.
